Caki-2 SETD2 KO cell line
Invented by Sergio F de Almeida at Instituto de Medicina Molecular João Lobo Antunes
Caki-2 DNMT3A KO cell line
Invented by Sergio F de Almeida
Invented at Instituto de Medicina Molecular João Lobo Antunes
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 160723 |
| Antigen/Gene or Protein Targets | DNA methyltransferase 3A |
| Parental Line | Clear cell renal cell carcinoma cell line (Caki-2) |
| Synonyms | TBRS, HESJAS |
| Host | Human |
| Tissue | Kidney |
| Model | Cancer Model |
| Relevance | Experimental ablation of DNMT3A gene expression using the CRISPR/Cas9 system renders Caki-2-DNMT3A knockout cells a valuable tool to investigate the role of DNA methylation in processes such as cell differentiation or cancer progression. |
| Production Details | CRISPR/Cas9 KO |
| Conditional | No |
| Research Area | Cancer, DNA Damage and Repair, Epigenetics & Nuclear Signalling, Gene Expression |
| Recommended Growing Conditions | Grow as monolayers in Dulbecco’s modified Eagle medium, supplemented with 10% (v/v) FBS, 1% (v/v) nonessential amino acids, 1% (v/v) L-glutamine and 100U/mL penicillin-streptomycin, at 37 °C in a humidified atmosphere with 5% CO2. |
| Notes |
Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license. |
References: 1 entry
References: 1 entry
Inventor Information
Inventors
|
Sergio F de Almeida |
